Rajesh C. Shrotriya, Chairman, Chief Executive Officer & President.

Thank you, Shiv, and good morning, everyone. These are exciting time to the Spectrum. Today we announced a planned acquisition of Allos Therapeutics. This represents an important and exciting opportunity for both of our companies. There are four critical takeaways for our investors.

Number one, this is a good deal for shareholders of both companies. The deal brings immediate diversification from a revenue-generating cancer drugs and is expected to be rapidly accretive to EPS in fourth quarter of this year.

Number two, there is unique synergy in a combination of Allos and Spectrum, FOLOTYN is prescribed by the same target physicians as ZEVALIN, while FUSILEV maybe helpful in reducing toxicity of FOLOTYN.

Number three, we believe FOLOTYN’s potential extends beyond PTCL. Remember, it is an improved methotrexate analog. And methotrexate is used to treat a variety of both liquid and solid tumors, such as breast cancer, acute lymphocytic leukemia and others.

Number four, in keeping with our philosophy of strong fiscal discipline, we don’t anticipate issuing even a single share of our stock to complete this transaction and that’s very important to us. I will now cover these points in greater depth. This acquisition further diversifies the Spectrum’s product revenue with an FDA approved novel anticancer drug, FOLOTYN, which is prescribed by the same physicians who prescribe ZEVALIN.